Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Oral OPRX-106 in Healthy Volunteers
NCT02107833Phase 1Completed
- Sponsor
- Protalix BioTherapeutics
- Start
- Jul 2014
- Primary completion
- Dec 2014
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of OPRX-106 in ulcerative colitis (UC) (3 cohorts), sponsored by Protalix BioTherapeutics. Primary endpoint: Adverse Events at 5 days. Started Jul 2014; status: completed.
02
Drugs
OPRX-106
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT02107833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02107833.